Renalytix (LSE:RENX) has announced further expansion of the U.S. clinical reach of its kidneyintelX.dkd test, following the completion of three new electronic health record–integrated deployments with regional kidney care providers in New York, Florida and Tennessee. Testing is now underway across these sites, with the rollout designed around streamlined, one-click ordering to support a gradual increase in utilisation.
The company is continuing with a disciplined and resource-efficient commercial strategy, while also strengthening its collaboration with Tempus AI. This partnership is focused on embedding kidneyintelX.dkd within the electronic records and data infrastructure of major health systems, laying the groundwork for broader geographic penetration and expanded clinical adoption over time. Alongside these operational developments, Renalytix has been increasing investor engagement, including participation at the J.P. Morgan Healthcare Conference, ahead of a broader trading and corporate update expected in February 2026.
From a market perspective, the outlook remains constrained by weak financial fundamentals, including substantial losses, negative equity and continued cash burn. Technical indicators are also negative, with the share price trading below key moving averages and a bearish MACD signal. While recent corporate progress and oversold technical conditions offer some support, these factors do not fully offset the prevailing financial and trend-related risks.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on improving the clinical management of chronic kidney disease. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in diabetic kidney disease. The company targets large physician groups and health systems across the United States, where kidneyintelX.dkd is commercially available and supported by real-world performance data, inclusion in international CKD guidelines, and full Medicare reimbursement of $950 per reportable result.
Leave a Reply